These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 14987833

  • 1. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Moreno A, Pérez S, Galiano S, Juanenea L, Erviti O, Frígola C, Aldana I, Monge A.
    Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Juanenea L, Galiano S, Erviti O, Moreno A, Pérez S, Aldana I, Monge A.
    Bioorg Med Chem; 2004 Sep 01; 12(17):4717-23. PubMed ID: 15358298
    [Abstract] [Full Text] [Related]

  • 3. A novel range based QSAR study of human neuropeptide Y (NPY) Y5 receptor inhibitors.
    Deswal S, Roy N.
    Eur J Med Chem; 2007 Apr 01; 42(4):463-70. PubMed ID: 17083999
    [Abstract] [Full Text] [Related]

  • 4. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
    Torrens A, Mas J, Port A, Castrillo JA, Sanfeliu O, Guitart X, Dordal A, Romero G, Fisas MA, Sánchez E, Hernández E, Pérez P, Pérez R, Buschmann H.
    J Med Chem; 2005 Mar 24; 48(6):2080-92. PubMed ID: 15771450
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
    Blum CA, Zheng X, De Lombaert S.
    J Med Chem; 2004 Apr 22; 47(9):2318-25. PubMed ID: 15084130
    [Abstract] [Full Text] [Related]

  • 6. Novel human neuropeptide Y Y5 receptor antagonists for the treatment of obesity. Synthesis and biological evaluation of pyridine hydrazide derivatives.
    Galiano S, Erviti O, Pérez S, Moreno A, Juanenea L, Aldana I, Monge A.
    Arzneimittelforschung; 2005 Apr 22; 55(2):81-5. PubMed ID: 15787274
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
    Gillman KW, Higgins MA, Poindexter GS, Browning M, Clarke WJ, Flowers S, Grace JE, Hogan JB, McGovern RT, Iben LG, Mattson GK, Ortiz A, Rassnick S, Russell JW, Antal-Zimanyi I.
    Bioorg Med Chem; 2006 Aug 15; 14(16):5517-26. PubMed ID: 16697206
    [Abstract] [Full Text] [Related]

  • 8. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D, Adham N, Hesk D, Wu Y, Kelly J, Huang Y, Guzzi M, Zhang X, McCombie S, Stamford A, Parker E.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):1-7. PubMed ID: 18976648
    [Abstract] [Full Text] [Related]

  • 9. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs.
    Levens NR, Della-Zuana O.
    Curr Opin Investig Drugs; 2003 Oct 28; 4(10):1198-204. PubMed ID: 14649211
    [Abstract] [Full Text] [Related]

  • 10. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
    Li G, Stamford AW, Huang Y, Cheng KC, Cook J, Farley C, Gao J, Ghibaudi L, Greenlee WJ, Guzzi M, van Heek M, Hwa JJ, Kelly J, Mullins D, Parker EM, Wainhaus S, Zhang X.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1146-50. PubMed ID: 18160282
    [Abstract] [Full Text] [Related]

  • 11. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.
    Mashiko S, Moriya R, Ishihara A, Gomori A, Matsushita H, Egashira S, Iwaasa H, Takahashi T, Haga Y, Fukami T, Kanatani A.
    Eur J Pharmacol; 2009 Aug 01; 615(1-3):113-7. PubMed ID: 19482021
    [Abstract] [Full Text] [Related]

  • 12. Modulation of neuropeptide Y receptors for the treatment of obesity.
    Sato N, Ogino Y, Mashiko S, Ando M.
    Expert Opin Ther Pat; 2009 Oct 01; 19(10):1401-15. PubMed ID: 19743896
    [Abstract] [Full Text] [Related]

  • 13. Novel potent neuropeptide Y Y5 receptor antagonists: synthesis and structure-activity relationships of phenylpiperazine derivatives.
    Takahashi T, Sakuraba A, Hirohashi T, Shibata T, Hirose M, Haga Y, Nonoshita K, Kanno T, Ito J, Iwaasa H, Kanatani A, Fukami T, Sato N.
    Bioorg Med Chem; 2006 Nov 15; 14(22):7501-11. PubMed ID: 16919461
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT, Hogan JB, Leahy CL, Flowers SC, Stanley JA, Ortiz AA, Poindexter GS.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):224-32. PubMed ID: 18573246
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
    Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, Nakatani Y, Ohsawa F, Nishikawa N, Sugai M, Suzuki M, Aoki K, Kitaguchi H.
    J Pharmacol Exp Ther; 2006 May 20; 317(2):562-70. PubMed ID: 16436501
    [Abstract] [Full Text] [Related]

  • 16. A preliminary study of the metabolic stability of a series of benzoxazinone derivatives as potent neuropeptide Y5 antagonists.
    Dordal A, Lipkin M, Macritchie J, Mas J, Port A, Rose S, Salgado L, Savic V, Schmidt W, Serafini MT, Spearing W, Torrens A, Yeste S.
    Bioorg Med Chem Lett; 2005 Aug 15; 15(16):3679-84. PubMed ID: 15982873
    [Abstract] [Full Text] [Related]

  • 17. Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
    Takahashi T, Haga Y, Sakamoto T, Moriya M, Okamoto O, Nonoshita K, Shibata T, Suga T, Takahashi H, Hirohashi T, Sakuraba A, Gomori A, Iwaasa H, Ohe T, Ishihara A, Ishii Y, Kanatani A, Fukami T.
    Bioorg Med Chem Lett; 2009 Jul 01; 19(13):3511-6. PubMed ID: 19464889
    [Abstract] [Full Text] [Related]

  • 18. Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.
    Ogino Y, Ohtake N, Nagae Y, Matsuda K, Ishikawa M, Moriya M, Kanesaka M, Mitobe Y, Ito J, Kanno T, Ishihara A, Iwaasa H, Ohe T, Kanatani A, Fukami T.
    Bioorg Med Chem Lett; 2008 Sep 15; 18(18):4997-5001. PubMed ID: 18752943
    [Abstract] [Full Text] [Related]

  • 19. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist.
    Omori N, Kouyama N, Yukimasa A, Watanabe K, Yokota Y, Tanioka H, Nambu H, Yukioka H, Sato N, Tanaka Y, Sekiguchi K, Okuno T.
    Bioorg Med Chem Lett; 2012 Mar 01; 22(5):2020-3. PubMed ID: 22300657
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists.
    Di Fabio R, Giovannini R, Bertani B, Borriello M, Bozzoli A, Donati D, Falchi A, Ghirlanda D, Leslie CP, Pecunioso A, Rumboldt G, Spada S.
    Bioorg Med Chem Lett; 2006 Mar 15; 16(6):1749-52. PubMed ID: 16364642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.